Target Name: LDHB
NCBI ID: G3945
Review Report on LDHB Target / Biomarker Content of Review Report on LDHB Target / Biomarker
LDHB
Other Name(s): LDHB variant 1 | L-lactate dehydrogenase B chain (isoform LDHB) | Lactate dehydrogenase H chain | lactate dehydrogenase B | LDH heart subunit | Epididymis secretory protein Li 281 | Lactate dehydrogenase B, transcript variant 1 | Renal carcinoma antigen NY-REN-46 | testicular secretory protein Li 25 | Lactate dehydrogenase B, transcript variant 2 | renal carcinoma antigen NY-REN-46 | LDHB variant 2 | L-Lactate dehydrogenase B | LDH-H | lactate dehydrogenase H chain | L-lactate dehydrogenase B chain (isoform LDHBx) | LDHB_HUMAN | epididymis secretory protein Li 281 | HEL-S-281 | Testicular secretory protein Li 25 | LDH-B | TRG-5 | LDHBD | L-lactate dehydrogenase B chain

LDHBv1: A Potential Drug Target and Biomarker

Long domain chain heat shock proteins (LDHB) are a family of proteins that are involved in various cellular processes, including DNA replication, transcription, and DNA damage repair. LDHB variants, such as LDHB variant 1 (LDHBv1), have been identified as potential drug targets or biomarkers for various diseases. In this article, we will discuss LDHBv1 and its potential applications as a drug target or biomarker.

Potential Applications of LDHBv1 as a Drug Target

LDHBv1 is a heat shock protein that is expressed in various tissues and cells, including brain, heart, liver, and pancreas. It plays a crucial role in ensuring the stability of DNA during times of increased thermal stress, such as during DNA replication or transcription. LDHBv1 has been shown to play a key role in the regulation of cellular processes that are critical for human health, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the potential applications of LDHBv1 as a drug target is its role in cancer. LDHBv1 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer. LDHBv1 has also been shown to play a role in the regulation of apoptosis, which is a critical mechanism that regulates cell death in cancer cells.

Another potential application of LDHBv1 as a drug target is its role in neurodegenerative diseases. LDHBv1 has been shown to play a role in the regulation of neurotransmitter synthesis and release, which is a critical step in the development and progression of neurodegenerative diseases.

Potential Applications of LDHBv1 as a Biomarker

LDHBv1 has also been identified as a potential biomarker for various diseases. For example, LDHBv1 has been shown to be involved in the regulation of insulin sensitivity, which is a critical factor in the development and progression of type 2 diabetes.

LDHBv1 has also been shown to play a role in the regulation of inflammation, which is a critical factor in the development and progression of various inflammatory diseases, including cardiovascular diseases.

Conclusion

In conclusion, LDHBv1 is a heat shock protein that has been shown to play a crucial role in various cellular processes that are critical for human health. As a result, LDHBv1 has potential applications as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of LDHBv1 in these diseases and to develop effective treatments.

Protein Name: Lactate Dehydrogenase B

Functions: Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+)

The "LDHB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LDHB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LDHBP1 | LDHC | LDHD | LDLR | LDLRAD1 | LDLRAD2 | LDLRAD3 | LDLRAD4 | LDLRAP1 | LDOC1 | LEAP2 | LECT2 | LEF1 | LEF1-AS1 | LEFTY1 | LEFTY2 | LEKR1 | LELP1 | LEMD1 | LEMD1-AS1 | LEMD2 | LEMD3 | LENEP | LENG1 | LENG8 | LENG8-AS1 | LENG9 | LEO1 | LEP | LEPR | LEPROT | LEPROTL1 | LERFS | LETM1 | LETM2 | LETMD1 | LETR1 | Leukotriene B4 receptor (LTB4-R) | Leukotriene CysLT receptor | LEUTX | LEXM | LFNG | LGALS1 | LGALS12 | LGALS13 | LGALS14 | LGALS16 | LGALS17A | LGALS2 | LGALS3 | LGALS3BP | LGALS4 | LGALS7 | LGALS7B | LGALS8 | LGALS8-AS1 | LGALS9 | LGALS9B | LGALS9C | LGALSL | LGI1 | LGI2 | LGI3 | LGI4 | LGMN | LGMNP1 | LGR4 | LGR5 | LGR6 | LGSN | LHB | LHCGR | LHFPL1 | LHFPL2 | LHFPL3 | LHFPL3-AS1 | LHFPL3-AS2 | LHFPL4 | LHFPL5 | LHFPL6 | LHFPL7 | LHPP | LHX1 | LHX2 | LHX3 | LHX4 | LHX4-AS1 | LHX5 | LHX6 | LHX8 | LHX9 | LIAS | LIF | LIFR | LIFR-AS1 | LIG1 | LIG3 | LIG4 | LILRA1 | LILRA2